-
Posted by
Two Blokes Jul 29 -
Filed in
Stock
-
1 view
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges.
